Experimental analysis highlights ascorbate's effectiveness against oxidative stress in HO-1 deficient cells, suggesting therapeutic potential.
Heme oxygenase-1 (HO-1) deficiency manifests with severe metabolic abnormalities, yet the underlying mechanisms remain incompletely understood. We investigated metabolic adaptations in HO-1 deficient cells using patient-derived lymphoblastoid cells (LCL) and HEK293T knockout cells. Both cell types demonstrated concurring metabolic signatures, including a substantial reduction in intracellular ascorbic acid levels despite compensatory upregulation of sodium-dependent vitamin C transporter 2 (SVCT2) and downregulation of GLUT1 compared to wild-type cells. Ultrastructural examination revealed abnormal mitochondrial morphology in both models. Both cell types showed higher baseline hydrogen peroxide levels compared to wild-type cells. Treatment with 2-phospho-L-ascorbic acid (AA2P) restored cell viability in both models upon hemin-induced stress, with protection requiring functional SVCT2-mediated uptake. AA2P supplementation attenuated the elevated H2O2 levels without altering glutathione redox homeostasis as measured by GSH/GSSG ratios. These findings illuminate ascorbic acid metabolism as a critical node in HO-1 deficiency pathophysiology and suggest ascorbic acid supplementation as a potential therapeutic strategy for this rare disorder.
No takes yet. Share an insight, caveat, or question.
Berendes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: